Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. May/Jun 2018;10(4):513-538.
doi: 10.1080/19420862.2018.1438797. Epub 2018 Mar 20.

Analytical Comparability Study of Recombinant Monoclonal Antibody Therapeutics

Free PMC article

Analytical Comparability Study of Recombinant Monoclonal Antibody Therapeutics

Alexandre Ambrogelly et al. MAbs. .
Free PMC article


Process changes are inevitable in the life cycle of recombinant monoclonal antibody therapeutics. Products made using pre- and post-change processes are required to be comparable as demonstrated by comparability studies to qualify for continuous development and commercial supply. Establishment of comparability is a systematic process of gathering and evaluating data based on scientific understanding and clinical experience of the relationship between product quality attributes and their impact on safety and efficacy. This review summarizes the current understanding of various modifications of recombinant monoclonal antibodies. It further outlines the critical steps in designing and executing successful comparability studies to support process changes at different stages of a product's lifecycle.

Keywords: comparability; post-translational modifications; recombinant monoclonal antibodies.

Similar articles

See all similar articles

Cited by 5 articles

MeSH terms


LinkOut - more resources